

Inventors: Ruoslahti and Pasqualini
Serial No.: 09/228,866
Filed: January 12, 1999
Page 2

✓ 14. (Amended) A peptide that selectively homes to brain, consisting of the amino acid sequence:

Sub D1
X₁SRLX₂ (SEQ ID NO: 45),

wherein X₁ and X₂ each is 1 to 10 independently selected amino acids

C1 Cont
and wherein said peptide exhibits at least two-fold greater specific binding to brain than to kidney.

15. (Amended) A peptide that selectively homes to brain, [The peptide of claim 14,] comprising the amino acid sequence CLSSRLDAC (SEQ ID NO: 3).

C2 Sub D2
17. (Amended) A peptide that selectively homes to brain, [The peptide of claim 14,] comprising the amino acid sequence CNSRLHLRC (SEQ ID NO: 1).

C3 Sub D3
19. (Amended) A peptide that selectively homes to brain [The peptide of claim 14,] comprising the amino acid sequence CNSRLQLRC (SEQ ID NO: 5).

Inventors: Ruoslahti and Pasqualini
Serial No.: 09/228,866
Filed: January 12, 1999
Page 3

21. (Amended) A conjugate, comprising a peptide that selectively homes to brain linked to a moiety, said peptide consisting of the amino acid sequence:

X₁SRLX₂ (SEQ ID NO: 45),

wherein X₁ and X₂ each is 1 to 10 independently selected amino acids,

wherein said peptide exhibits at least two-fold greater specific binding to brain than to kidney and

wherein said moiety is selected from the group consisting of a toxin, drug, chemotherapeutic agent, cell and liposome.

24. (Amended) A peptide that selectively homes to brain consisting of the amino acid sequence:

X₃VLRX₄ (SEQ ID NO: 46),

wherein X₃ is absent or is 1 to 10 independently selected amino acids and X₄ is 1 to 20 independently selected amino acids, and wherein said peptide is cyclic and exhibits at least two-fold greater specific binding to brain than to kidney.

Inventors: Ruoslahti and Pasqualini
Serial No.: 09/228,866
Filed: January 12, 1999
Page 4

25. (Amended) A conjugate, comprising a peptide that selectively homes to brain linked to a moiety, said peptide consisting of the amino acid sequence:

X₃VLRX₄ (SEQ ID NO: 46),

wherein X₃ is absent or is 1 to 10 independently selected amino acids and X₄ is 1 to 20 independently selected amino acids,

wherein said peptide exhibits at least two-fold greater specific binding to brain than to kidney and

wherein said moiety is selected from the group consisting of a toxin, drug, chemotherapeutic agent, cell and liposome.

II. REMARKS

Claims 13 to 41 are pending with claims 13, 21 to 23 and 25 to 27 withdrawn from consideration. Claims 13, 14, 21, 24 and 25 have been amended herein. Claims 14 to 20, 24 and 28 to 41 are presently under examination.

Applicants' representative appreciates the Examiner's time and helpful comments made in the telephonic interview on June 30, 2000.